Asset profile
Envafolimab
Monoclonal antibody
Evidence outlook · registrational
Non-Small Cell Lung Cancer: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. Registrational readout expected around 2027-12-30.
NCT05068427: The study was an open-label, single-arm trial of 34 patients receiving chidamide plus envafolimab, with no randomized control group for comparison. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Also in development:HIV · Phase 2Chronic Hepatitis B · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
172 competitors in this universe: 10 direct rivals (same mechanism and indication), 1 same-class, 161 same-indication; 88 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Envafolimab: this drug | Phase 3 | Monoclonal antibody | PD-L1 | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | ||
| Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs) | Approved | Monoclonal antibody | PD-L1 | ||
| Adebrelimab | Phase 3 | Monoclonal antibody | PD-L1 | ||
| CS1001 Monoclonal Antibody | Phase 3 | Monoclonal antibody | PD-L1 | ||
| KL-A167 | Phase 3 | Monoclonal antibody | PD-L1 | ||
| PF-08046054 | Phase 3 | Antibody–drug conjugate | PD-L1 | ||
| HLX43 | Phase 2/3 | Antibody–drug conjugate | PD-L1 | ||
| 177Lu-RAD204 | Phase 1 | Radiopharmaceutical | PD-L1 | ||
| BPI-371153 | Phase 1 | Small molecule | PD-L1 | ||
| IBC-Ab002 | Phase 1 | Monoclonal antibody | PD-L1 | ||
| Adefovir Dipivoxil (Hepsera) | Approved | Small molecule | — | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A |
…and 157 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
4 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(32 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (10)
November 2026 (1)
What to watch
December 2026 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (15)
January 2027 (1)
What to watch
February 2027 (2)
May 2027 (3)
What to watch
What to watch
What to watch
June 2027 (2)
July 2027 (1)
What to watch
August 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (4)
What to watch
What to watch
What to watch
What to watch
2028 (3)
March 2028 (1)
What to watch
April 2028 (1)
What to watch
September 2028 (1)
What to watch
2029 (4)
January 2029 (1)
What to watch
March 2029 (1)
What to watch
June 2029 (1)
What to watch
October 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.